M. Bouattour

机构：Inserm, Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris, Centre de Recherche sur l'Inflammation

发表论文 7 篇 · 总被引 43 次 · h-index 2

代表论文

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) (2022 · Annals of Oncology · 被引 26)
Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. (2026 · Journal of Clinical Oncology · 被引 13)
Results from the safety lead-in for a phase 1b/2 study of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. (2026 · Journal of Clinical Oncology · 被引 2)
IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. (2026 · Journal of Clinical Oncology · 被引 1)
Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study (2026 · Hepatology Communications · 被引 1)
1499P Interim analysis of the REFINE-IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy (2025 · Annals of Oncology)